Hospital
Warren General Hospital
Warren General Hospital was paid $3.80M by Medicaid between Jan 2018 and Dec 2024, across 184 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoWARREN GENERAL HOSPITAL
WARREN, PA 16365
WARREN, PA 16365
33aNPI1659360220assigned 10/17/2005
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$3.80M
24GClaims152,177
24DCodes billed184
24AFirst – last monthJan 2018 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 54 | $206.66 | |
| 2019 | 438 | $2K | |
| 2020 | 12,527 | $175K | |
| 2021 | 68,397 | $1.38M | |
| 2022 | 25,615 | $966K | |
| 2023 | 24,405 | $724K | |
| 2024incomplete | 20,741 | $548K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 9,702 | 9,404 | $594K |
| G0378 | Hospital observation service, per hour | 12% | 502 | 462 | $444K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 5,000 | 4,808 | $421K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 8.8% | 4,182 | 4,086 | $335K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 7.6% | 3,933 | 3,794 | $290K |
| 87634 | 6.5% | 4,191 | 4,095 | $247K | |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 6.4% | 7,035 | 2,063 | $242K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.2% | 2,886 | 2,746 | $83K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.1% | 1,201 | 1,107 | $81K |
| 80053 | Comprehensive metabolic panel | 2.0% | 8,973 | 7,687 | $76K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 431 | 413 | $58K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 1,153 | 1,027 | $56K |
172 more codes
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 2,057 | $52K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 11,815 | $50K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1.3% | 2,587 | $48K |
| 80050 | General health panel | 1.2% | 1,021 | $45K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 1,351 | $37K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,816 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,127 | $26K |
| 80061 | Lipid panel | <1% | 2,114 | $26K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,638 | $24K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 468 | $23K |
| 83735 | <1% | 4,875 | $23K | |
| 81000 | <1% | 6,268 | $21K | |
| 84484 | <1% | 3,004 | $20K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 241 | $18K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 341 | $16K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 248 | $15K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 732 | $15K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 202 | $15K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 859 | $15K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 697 | $15K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 427 | $14K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 620 | $11K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 86 | $10K |
| 80076 | <1% | 1,366 | $10K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,419 | $9K |
| 97161 | <1% | 238 | $9K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 3,191 | $9K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 760 | $9K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 359 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 355 | $9K |
| 94760 | <1% | 5,111 | $8K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 817 | $8K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 143 | $7K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,197 | $7K |
| 83690 | <1% | 1,727 | $7K | |
| 87040 | <1% | 672 | $7K | |
| 87088 | <1% | 930 | $6K | |
| 87070 | <1% | 869 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 900 | $6K |
| 83605 | <1% | 1,071 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 241 | $5K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 111 | $5K |
| 82728 | <1% | 531 | $5K | |
| 84481 | <1% | 192 | $5K | |
| 73564 | <1% | 278 | $5K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 401 | $5K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 155 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 99 | $5K |
| 71045 | Radiologic examination, chest; single view | <1% | 860 | $4K |
| 83880 | <1% | 264 | $4K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 278 | $4K |
| 86885 | <1% | 515 | $4K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 774 | $4K |
| 84703 | <1% | 413 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 25 | $3K |
| 82607 | <1% | 310 | $3K | |
| 84439 | <1% | 443 | $3K | |
| 88142 | <1% | 181 | $3K | |
| 73630 | <1% | 281 | $3K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 70 | $3K |
| 85379 | <1% | 378 | $3K | |
| 87186 | <1% | 387 | $3K | |
| 73030 | <1% | 187 | $3K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 86 | $3K |
| 73610 | <1% | 170 | $3K | |
| 87077 | <1% | 438 | $3K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 12 | $3K |
| 0011A | <1% | 79 | $2K | |
| 86618 | <1% | 117 | $2K | |
| 84702 | <1% | 146 | $2K | |
| 87430 | <1% | 335 | $2K | |
| 73110 | <1% | 225 | $2K | |
| 85610 | <1% | 820 | $2K | |
| 85730 | <1% | 438 | $2K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 31 | $2K |
| 86900 | <1% | 531 | $2K | |
| 82043 | <1% | 266 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 69 | $2K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 51 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 370 | $2K |
| 72110 | <1% | 106 | $2K | |
| 73502 | <1% | 107 | $2K | |
| 83540 | <1% | 264 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 128 | $2K |
| 84436 | <1% | 200 | $2K | |
| 71250 | <1% | 31 | $2K | |
| 86901 | <1% | 428 | $2K | |
| 84466 | <1% | 113 | $1K | |
| 73130 | <1% | 129 | $1K | |
| 97165 | <1% | 38 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,398 | $1K |
| 0012A | <1% | 28 | $1K | |
| 82248 | <1% | 171 | $1K | |
| 96376 | <1% | 337 | $1K | |
| 84550 | <1% | 217 | $1K | |
| 86592 | <1% | 259 | $1K | |
| 85651 | <1% | 413 | $997.56 | |
| 86480 | <1% | 14 | $992.13 | |
| 84153 | <1% | 40 | $964.16 | |
| X0592 | <1% | 154 | $933.42 | |
| 84479 | <1% | 109 | $926.90 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 252 | $879.80 |
| 96367 | <1% | 49 | $835.88 | |
| 81025 | <1% | 243 | $829.60 | |
| 74018 | <1% | 74 | $802.42 | |
| 84146 | <1% | 29 | $744.39 | |
| 86038 | <1% | 57 | $744.19 | |
| 36591 | <1% | 348 | $638.82 | |
| 82652 | <1% | 12 | $629.24 | |
| 83615 | <1% | 118 | $620.12 | |
| 93971 | <1% | 16 | $614.68 | |
| 97597 | <1% | 26 | $610.56 | |
| V2020 | Frames, purchases | <1% | 12 | $591.96 |
| 76801 | <1% | 15 | $585.06 | |
| 76830 | Ultrasound, transvaginal | <1% | 17 | $580.49 |
| 76775 | <1% | 18 | $538.81 | |
| 93226 | <1% | 13 | $513.74 | |
| 82565 | <1% | 87 | $503.75 | |
| 0001A | <1% | 14 | $480.00 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 27 | $476.32 |
| 90715 | <1% | 24 | $437.72 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 16 | $420.00 |
| 86140 | <1% | 143 | $381.20 | |
| 72052 | <1% | 13 | $356.50 | |
| 76642 | <1% | 12 | $354.52 | |
| 84460 | <1% | 53 | $341.67 | |
| 83550 | <1% | 87 | $339.83 | |
| 82746 | <1% | 39 | $326.99 | |
| 88174 | <1% | 12 | $312.85 | |
| J2704 | Injection, propofol, 10 mg | <1% | 522 | $278.20 |
| 84520 | <1% | 50 | $245.70 | |
| 93225 | <1% | 13 | $237.07 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 26 | $202.50 |
| 86803 | <1% | 12 | $186.20 | |
| 73080 | <1% | 17 | $179.80 | |
| 82962 | <1% | 244 | $174.02 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 34 | $172.48 |
| 86430 | <1% | 27 | $165.36 | |
| 87340 | <1% | 14 | $153.06 | |
| 84450 | <1% | 28 | $148.25 | |
| 82247 | <1% | 22 | $142.71 | |
| 74019 | <1% | 12 | $141.08 | |
| 87081 | <1% | 24 | $119.60 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 850 | $117.79 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 193 | $117.00 |
| 82803 | <1% | 17 | $114.97 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 177 | $101.36 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 696 | $101.29 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 588 | $95.89 |
| 82550 | <1% | 14 | $92.04 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 222 | $83.34 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 382 | $80.34 |
| 20610 | <1% | 52 | $73.61 | |
| 82140 | <1% | 13 | $58.00 | |
| 94664 | <1% | 16 | $50.82 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 348 | $43.26 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,129 | $42.87 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 186 | $26.43 |
| G0008 | Administration of influenza virus vaccine | <1% | 47 | $22.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 65 | $14.28 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 43 | $11.31 |
| 93041 | <1% | 131 | $10.94 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 299 | $10.41 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 454 | $6.52 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 33 | $2.32 |
| 90662 | <1% | 19 | $1.19 | |
| 91301 | <1% | 98 | $0.82 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 15 | $0.00 |
| 3049F | 0% | 13 | $0.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 27 | $0.00 |
| 3050F | 0% | 13 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSNYDER, JULIE (EXEC. DIRECTOR OF FINANCE)
| Provider | Location | Paid |
|---|---|---|
| Warren General Hospital | Warren, PA | $280K |
| Warren General Hospital | Warren, PA | $12K |
| Warren General Hospital | Warren, PA | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.